Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are important causes of chronic liver disease in the United States. The NASH Clinical Research Network (NASH CRN) was established in 2002 to conduct research related to its clinical features, risk factors, pathogenesis, natural history and treatment in children and adults. The initial funding period of the NASH CRN has been very productive in establishing and conducting network-wide protocols and numerous ancillary and pilot studies. Encouraged by its success, the NIDDK has issued RFA-DK-08-505 whose objective is to continue the NASH CRN for additional five years. The objectives of the NASH CRN during the next funding period are (a) to successfully complete three network-wide studies initiated during the initial funding period. They are an observational longitudinal study of NAFLD in adults and children (NAFLD Database study, n=1,215), a randomized double blind controlled therapeutic study of NASH in non-diabetic adults (PIVENS, n=247), and a randomized double blind controlled therapeutic study of NAFLD in children (TONIC, n=173). The NAFLD Database study may be amended to meet additional goals during the next funding period. These modifications may include extending the length of follow-up of those enrolled, consideration of a follow-up liver biopsy in a subset of patients without cirrhosis for better assessment of histological natural history and enrolling carefully chosen controls without NAFLD;(b) to successfully complete a large of ancillary studies and pilot studies that have been begun during the initial funding period;(c) to conduct additional therapeutic studies in adults and children with NASH as options currently available to treat NASH are quite limited. Subsets of patients requiring immediate attention include (but not limited) to those with diabetes or cirrhosis and (d) to initiate and complete additional ancillary studies based on extensive clinical material and biosamples collected thus far. These studies may focus on (but are not limited to) natural history of NAFLD and NASH in children and adults, non-invasive assessment of disease severity (e.g., proteomics, lipodimics, clinical prediction rules) and disease pathogenesis (cytokine analyses, genome-wide association studies, tissue proteomics). Two new ancillary studies proposed by the UCSF Clinical Center aim to: a) Develop a non-invasive alternative to liver biopsy for the evaluation and monitoring of hepatic fibrosis in NAFLD CRN patients using novel MRI imaging and MR spectroscopic techniques, and b) Elucidate the impact of NAFLD on cardiac lipotoxicity, cardiac energetics, and myocardial function in NASH CRN patients using cardiac MRI and proton mass spectroscopy.

Public Health Relevance

(provided by the applicant): NAFLD and NASH are important health problems and their incidence is expected to increase. During the initial funding period, the NASH CRN has made important contributions to the field of NAFLD and NASH, however there remain numerous unanswered questions. During the next funding period, the CRN will continue to investigate risk factors, clinical aspects, natural history and optimal treatment for NASH and associated conditions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK061738-11S2
Application #
8600763
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (M1))
Program Officer
Doo, Edward
Project Start
2002-06-15
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
11
Fiscal Year
2013
Total Cost
$30,283
Indirect Cost
$10,933
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Bambha, Kiran; Wilson, Laura A; Unalp, Aynur et al. (2014) Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 34:1250-8
Molleston, Jean P; Schwimmer, Jeffrey B; Yates, Katherine P et al. (2014) Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 164:707-713.e3
St-Jules, David E; Watters, Corilee A; Brunt, Elizabeth M et al. (2013) Estimation of Fish And Omega-3 Fatty Acid Intake In Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr :
Chen, Qing-Rong; Braun, Rosemary; Hu, Ying et al. (2013) Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One 8:e65982
Vos, Miriam B; Colvin, Ryan; Belt, Patricia et al. (2012) Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr 54:90-6
Guerrerio, Anthony L; Colvin, Ryan M; Schwartz, Amy K et al. (2012) Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr 95:892-900
Dunn, Winston; Sanyal, Arun J; Brunt, Elizabeth M et al. (2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 57:384-91
Bambha, Kiran; Belt, Patricia; Abraham, Maria et al. (2012) Ethnicity and nonalcoholic fatty liver disease. Hepatology 55:769-80
Guy, Cynthia D; Suzuki, Ayako; Zdanowicz, Marzena et al. (2012) Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 55:1711-21
Kowdley, Kris V; Belt, Patricia; Wilson, Laura A et al. (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55:77-85

Showing the most recent 10 out of 36 publications